-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Reiterates Buy on Inozyme Pharma, Maintains $16 Price Target

Benzinga·04/10/2025 15:07:26
Listen to the news
HC Wainwright & Co. analyst Edward White reiterates Inozyme Pharma (NASDAQ:INZY) with a Buy and maintains $16 price target.